2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p
=0.4. Risk of PCR+ at day 14, RR 0.76, p
This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p
Although the viral clearance result is not statistically significant, it is consistent with the significant 20% improved viral clearance [10‑29%]
from meta analysis of the 41 viral clearance results to date
Chen et al., 10 Jul 2020, Randomized Controlled Trial, Taiwan, peer-reviewed, 19 authors.